From the Journals

COVID-19: Extra caution needed for patients with diabetes


 

FROM DIABETES & METABOLIC SYNDROME

After a diagnosis

If patients with diabetes develop COVID-19, then home management may still be possible, wrote the authors, who recommended basic treatment measures such as maintaining hydration and managing symptoms with acetaminophen and steam inhalation, and home isolation for 14 days or until the symptoms resolve.

In the event of hyperglycemia with fever in patients with type 1 diabetes, blood glucose and urinary ketones should be monitored often. “Frequent changes in dosage and correctional bolus may be required to maintain normoglycemia,” they cautioned.

Concerning diabetic drug regimens, they suggest patients avoid antihyperglycemic agents that can cause volume depletion or hypoglycemia and, if necessary, that they reduce oral antidiabetic drugs and follow sick-day guidelines.

For hospitalized patients, the investigators strengthened that statement, advising that oral agents need to be stopped, particularly sodium-glucose cotransporter 2 inhibitors and metformin. “Insulin is the preferred agent for control of hyperglycemia in hospitalized sick patients,” they wrote.


Untested therapies

The authors also discussed a range of untested therapies that may help fight COVID-19, such as antiviral drugs (such as lopinavir and ritonavir), zinc nanoparticles, and vitamin C. Supplementing those recommendations, Dr. Gupta and colleagues provided a concise review of COVID-19 epidemiology and extant data relevant to patients with diabetes.

The investigators reported no conflicts of interest.

SOURCE: Gupta et al. Diabetes Metab Syndr. 2020;14(3):211-12.

Pages

Recommended Reading

RYGB tops sleeve gastrectomy in long-term outcomes for diabetes
MDedge Internal Medicine
Biomarker pattern flags risk for microalbuminuria in diabetes patients
MDedge Internal Medicine
Study: Glycemic control improved in fasting diabetic Muslims
MDedge Internal Medicine
CMS to test model limiting out-of-pocket costs for insulin
MDedge Internal Medicine
Belapectin misses endpoints in NASH trial
MDedge Internal Medicine
Risk factors for death from COVID-19 identified in Wuhan patients
MDedge Internal Medicine
FDA to revise safety evaluation of type 2 diabetes drugs
MDedge Internal Medicine
Internist reports from COVID-19 front lines near Seattle
MDedge Internal Medicine
Smoking, hypoglycemia, kidney function tied to vision loss in type 2 diabetes
MDedge Internal Medicine
CV health in pregnancy improves outcomes for mother and infant
MDedge Internal Medicine